Importantly, in a pooled analysis of four studies, pembrolizumab was shown to reduce the risk of death by 17% compared to chemotherapy in patients with baseline brain metastases and NSCLC with PD-L1 expression >1% (41). Here, CD274 is linked to non-small cell lung carcinoma.